<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "2: products must gain market acceptance", fill: "#96ded1"},
{source: "2: products must gain market acceptance", target: "2: increase revenue", fill: "#96ded1"},
{source: "2: products must gain market acceptance", target: "4: market introduction", fill: "#008000"},
{source: "4: market introduction", target: "4: competitive products", fill: "#008000"},
{source: "4: market introduction", target: "6: Significant ", fill: "#536895"},
{source: "6: Significant ", target: "6: competitive factors", fill: "#536895"},
{source: "6: competitive factors", target: "6: regulatory approval", fill: "#536895"},
{source: "6: regulatory approval", target: "6: product availability", fill: "#536895"},
{source: "6: product availability", target: "6: acceptance", fill: "#536895"},
{source: "6: acceptance", target: "6: application", fill: "#536895"},
{source: "6: application", target: "6: sales capabilities", fill: "#536895"},
{source: "6: sales capabilities", target: "6: product attributes relative", fill: "#536895"},
{source: "6: product attributes relative", target: "6: exclusivity through patent protection", fill: "#536895"},
{source: "6: Significant ", target: "7: research development", fill: "#e52b50"},
{source: "7: research development", target: "7: commercialization efforts may", fill: "#e52b50"},
{source: "7: commercialization efforts may", target: "7: competitors may", fill: "#e52b50"},
{source: "7: competitors may", target: "7: commercialize", fill: "#e52b50"},
{source: "7: commercialize", target: "7: effective", fill: "#e52b50"},
{source: "7: effective", target: "7: diagnostic products", fill: "#e52b50"},
{source: "7: research development", target: "21: Companys ", fill: "#ffc0cb"},
{source: "21: Companys ", target: "21: adverse impact on", fill: "#ffc0cb"},
{source: "21: Companys ", target: "22: environmental legislation", fill: "#a7fc00"},
{source: "22: environmental legislation", target: "22: regulations", fill: "#a7fc00"},
{source: "22: regulations", target: "22: most applicable", fill: "#a7fc00"},
{source: "22: environmental legislation", target: "30: manufacture", fill: "#9b870c"},
{source: "30: manufacture", target: "30: commercial quantities", fill: "#9b870c"},
{source: "30: commercial quantities", target: "30: costeffective", fill: "#9b870c"},
{source: "30: manufacture", target: "35: success depends on", fill: "#483d8b"},
{source: "35: success depends on", target: "35: continued ability", fill: "#483d8b"},
{source: "35: continued ability", target: "35: highly qualified personnel", fill: "#483d8b"},
{source: "35: highly qualified personnel", target: "35: current executive officers", fill: "#483d8b"},
{source: "35: current executive officers", target: "35: key employees", fill: "#483d8b"},
{source: "35: success depends on", target: "39: commercial success will depend", fill: "#ffdb58"},
{source: "39: commercial success will depend", target: "39: patent protection on", fill: "#ffdb58"},
{source: "39: patent protection on", target: "39: successfully defending", fill: "#ffdb58"},
{source: "39: successfully defending", target: "39: patents against third party", fill: "#ffdb58"},
{source: "39: patents against third party", target: "39: challenges", fill: "#ffdb58"},
{source: "39: commercial success will depend", target: "44: infringement", fill: "#483c32"},
{source: "44: infringement", target: "44: others may", fill: "#483c32"},
{source: "44: others may", target: "44: proprietary", fill: "#483c32"},
{source: "44: proprietary", target: "44: will prevent", fill: "#483c32"},
{source: "44: will prevent", target: "44: marketed unless", fill: "#483c32"},
{source: "44: infringement", target: "45: collaborators", fill: "#ffdab9"},
{source: "45: collaborators", target: "45: enjoin commercial", fill: "#ffdab9"},
{source: "45: enjoin commercial", target: "45: activities", fill: "#ffdab9"},
{source: "45: activities", target: "45: liability", fill: "#ffdab9"},
{source: "45: liability", target: "45: manufacture", fill: "#ffdab9"},
{source: "45: manufacture", target: "45: affected products", fill: "#ffdab9"},
{source: "45: collaborators", target: "48: rely on trade secrets", fill: "#7fff00"},
{source: "48: rely on trade secrets", target: "48: protect technology", fill: "#7fff00"},
{source: "48: protect technology", target: "48: patent protection", fill: "#7fff00"},
{source: "48: patent protection", target: "48: appropriate", fill: "#7fff00"},
{source: "48: rely on trade secrets", target: "START_HERE", fill: "#7fff00"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Application Software</td>
    </tr>
    <tr>
      <td>Health Care Facilities</td>
    </tr>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
    <tr>
      <td>Fertilizers and Agricultural Chemicals</td>
    </tr>
    <tr>
      <td>Diversified Chemicals</td>
    </tr>
    <tr>
      <td>Specialty Chemicals</td>
    </tr>
    <tr>
      <td>Food Distributors</td>
    </tr>
    <tr>
      <td>Trading Companies and Distributors</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Crime</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Cooperate</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Military</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Request</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Host meeting</td>
    </tr>
    <tr>
      <td>Seize</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Human death</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Solicit support</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Capital_gains_tax">Capital gains tax</a></td>
      <td>A capital gains tax (CGT) is a tax on the profit realized on the sale of a non-inventory asset. The most common capital gains are realized from the sale of stocks, bonds, precious metals, real estate, and property.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/New_product_development">New product development</a></td>
      <td>In business and engineering, new product development (NPD) covers the complete process of bringing a new product to market, renewing an existing product or introducing a product in a new market. A central aspect of NPD is product design, along with various business considerations.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Significant_figures">Significant figures</a></td>
      <td>Significant figures (also known as the significant digits, precision or resolution) of a number in positional notation are digits in the number that are reliable and necessary to indicate the quantity of something.\nIf a number expressing the result of a measurement (e.g., length, pressure, volume, or mass) has more digits than the number of digits allowed by the measurement resolution, then only as many digits as allowed by the measurement resolution are reliable, and so only these can be significant figures.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Significant_Others">Significant Others</a></td>
      <td>The term significant other (SO) has different uses in psychology and in colloquial language. Colloquially "significant other" is used as a gender-neutral term for a person's partner in an intimate relationship without disclosing or presuming anything about marital status, relationship status, gender identity, or sexual orientation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Significant_Mother">Significant Mother</a></td>
      <td>Significant Mother is an American television sitcom created by Erin Cardillo and Richard Keith. Starring Josh Zuckerman, Nathaniel Buzolic and Krista Allen, it premiered on The CW network on August 3 and ended its run on October 5, 2015.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Internet">Internet</a></td>
      <td>In finance and economics, interest is payment from a borrower or deposit-taking financial institution to a lender or depositor of an amount above repayment of the principal sum (that is, the amount borrowed), at a particular rate. It is distinct from a fee which the borrower may pay the lender or some third party.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Product_liability">Product liability</a></td>
      <td>Product liability is the area of law in which manufacturers, distributors, suppliers, retailers, and others who make products available to the public are held responsible for the injuries those products cause. Although the word "product" has broad connotations, product liability as an area of law is traditionally limited to products in the form of tangible personal property.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Cellulosic_ethanol">Cellulosic ethanol</a></td>
      <td>Cellulosic ethanol is ethanol (ethyl alcohol) produced from cellulose (the stringy fiber of a plant) rather than from the plant's seeds or fruit. It can be produced from grasses, wood, algae, or other plants.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bioprospecting">Bioprospecting</a></td>
      <td>Bioprospecting (also known as biodiversity prospecting) is the exploration of natural sources for small molecules, macromolecules and biochemical and genetic information that could be developed into commercially valuable products for the agricultural, aquaculture, bioremediation, cosmetics, nanotechnology, or pharmaceutical industries. In the pharmaceutical industry, for example,  almost one third of all small-molecule drugs approved by the U.S. Food and Drug Administration (FDA) between 1981 and 2014 were either natural products or compounds derived from natural products.Terrestrial plants, fungi and actinobacteria have been the focus of many past bioprospecting programs, but interest is growing in less explored ecosystems (e.g.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/The_Managed_Heart">The Managed Heart</a></td>
      <td>The Managed Heart: Commercialization of Human Feeling, by Arlie Russell Hochschild, was first published in 1983. A 20th Anniversary edition with a new afterword added by the author was published in 2003.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Commercialization_of_love">Commercialization of love</a></td>
      <td>The notion of commercialization of love, that is not to be confused with prostitution (the commercialization of sexual activity), involves the definitions of romantic love and consumerism.\n\n\n== Sociological development ==\nThe commercialization of love is the ongoing process of infiltration of commercial and economical stimuli in the daily life of lovers and the association of monetary and non-monetary symbols and commodities in the love relationships.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Lluís_Companys">Lluís Companys</a></td>
      <td>Lluís Companys i Jover (Catalan pronunciation: [ʎuˈis kumˈpaɲs]; 21 June 1882 – 15 October 1940) was a Spanish politician from Catalonia who served as president of Catalonia from 1934 and during the Spanish Civil War.\nCompanys was a lawyer close to labour movement and one of the most prominent leaders of the Republican Left of Catalonia (ERC) political party, founded in 1931.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Passeig_de_Lluís_Companys,_Barcelona">Passeig de Lluís Companys, Barcelona</a></td>
      <td>Passeig de Lluís Companys (Catalan pronunciation: [pəˈsɛdʒ də ʎuˈis kumˈpaɲs]) is a promenade in the Ciutat Vella and Eixample districts of Barcelona, Catalonia, Spain, and can be seen as an extension of Passeig de Sant Joan. It was named after President Lluís Companys, who was executed in 1940.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Companys,_procés_a_Catalunya">Companys, procés a Catalunya</a></td>
      <td>Companys, procés a Catalunya (Spanish: Companys, proceso a Cataluña) is a 1979 Spanish Catalan drama film directed by Josep Maria Forn, based on the last months of the life of the President of Catalonia, Lluís Companys, in which he shows his detention by the Nazis and his subsequent execution by the Spanish Francoists. It competed in the Un Certain Regard section at the 1979 Cannes Film Festival.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Holding_company">Holding company</a></td>
      <td>A holding company is a company whose primary business is holding a controlling interest in the securities of other companies. A holding company usually does not produce goods or services itself.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Formula_One_regulations">Formula One regulations</a></td>
      <td>The numerous Formula One regulations, made and enforced by the FIA and later the FISA, have changed dramatically since the first Formula One World Championship in 1950. This article covers the current state of F1 technical and sporting regulations, as well as the history of the technical regulations since 1950.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/New_York_Codes,_Rules_and_Regulations">New York Codes, Rules and Regulations</a></td>
      <td>The New York Codes, Rules and Regulations (NYCRR) contains New York state rules and regulations. The NYCRR is officially compiled by the New York State Department of State's Division of Administrative Rules.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Grasshopper_Manufacture">Grasshopper Manufacture</a></td>
      <td>Grasshopper Manufacture Inc. (株式会社グラスホッパー・マニファクチュア, Kabushiki Gaisha Gurasuhoppā Manifakuchua) is a Japanese video game developer founded on March 30, 1998 by Goichi Suda.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Manufacture_d'horlogerie">Manufacture d'horlogerie</a></td>
      <td>Manufacture d'horlogerie (meaning "watchmaking manufacturer") is a French language term of horology that has also been adopted in the English language as a loanword. In horology, the term is usually encountered in its abbreviated form manufacture.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Build-on-demand">Build-on-demand</a></td>
      <td>Build-on-demand or manufacturing on demand (MOD) refers to a manufacturing process where goods are produced only when or as they are required. This allows scalability and adjustable assemblies depending on the current needs of the part requestor or client.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Manufacture_nationale_de_Sèvres">Manufacture nationale de Sèvres</a></td>
      <td>The Manufacture nationale de Sèvres is one of the principal European porcelain factories. It is located in Sèvres, Hauts-de-Seine, France.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Computer-aided_manufacturing">Computer-aided manufacturing</a></td>
      <td>Computer-aided manufacturing (CAM) also known as computer-aided modeling or computer-aided machining is the use of software to control machine tools in the manufacturing of work pieces. This is not the only definition for CAM, but it is the most common; CAM may also refer to the use of a computer to assist in all operations of a manufacturing plant, including planning, management, transportation and storage.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Key_employee">Key employee</a></td>
      <td>Key employee, in U.S. Internal Revenue Service (IRS) terminology, is an employee classification used when determining if company-sponsored qualified retirement plans, including 401(a) defined benefit plans and 401(k)s, are considered "top-heavy" or, in other words, weighted towards the company's more highly compensated individuals.A key employee is defined by the IRS as an employee, either living or dead, who meets one of the following three criteria:\n\nAn officer making over $175,000 in 2018 or $180,000 in 2019 (the income threshold is indexed by the IRS and may increase each year);\nA 5% owner of the business (defined as one who either owns more than 5% of the business, or is credited with more than 5% ownership of the business through Family-Attribution Rules), or\nAn employee owning more than 1% of the business and making over $150,000 for the plan year.All other employees are referred to as non-key employees.There are some similarities between key employees and so-called highly compensated employees (HCE), but the compensation salary threshold is lower for HCEs, at only $120,000 versus $150,000 for key employees.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Golden_handcuffs">Golden handcuffs</a></td>
      <td>Golden handcuffs, a phrase first recorded in 1976, refers to financial allurements and benefits that have the objective to encourage highly compensated employees to remain within a company or organization instead of moving from company to company (or organization to organization) (opposite of a golden parachute). Golden handcuffs come in different forms, such as employee stock options or restricted stock, which endow only when the employee has been with the company or organization for a certain number of years, and contractual agreements, consisting of bonuses or other forms of benefits which must be repaid to the company if the employee leaves before the date agreed on.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Corporate-owned_life_insurance">Corporate-owned life insurance</a></td>
      <td>Corporate-owned life insurance (COLI), is life insurance on employees' lives that is owned by the employer, with benefits payable either to the employer or directly to the employee's families. Other names for the practice include janitor's insurance and dead peasants insurance.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/401(k)">401(k)</a></td>
      <td>40,000 (forty thousand) is the natural number that comes after 39,999 and before 40,001. It is the square of 200.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Patent_claim">Patent claim</a></td>
      <td>In a patent or patent application, the claims define, in technical terms, the extent, i.e. the scope, of the protection conferred by a patent, or the protection sought in a patent application.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Proprietary_colony">Proprietary colony</a></td>
      <td>A proprietary colony was a type of English colony mostly in North America and in the Caribbean in the 17th century.  In the British Empire, all land belonged to the monarch, and it was his/her prerogative to divide.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Proprietary_church">Proprietary church</a></td>
      <td>During the Middle Ages, a proprietary church (Latin ecclesia propria, German Eigenkirche) was a church, abbey or cloister built on private ground by a feudal lord, over which he retained proprietary interests, especially the right of what in English law is "advowson", that of nominating the ecclesiastic personnel.\n\n\n== History ==\nIn the later Roman Empire the church had been centrally organized: all monasteries and churches within a diocese, including their personnel and their properties, were under the jurisdiction of the local bishop.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Freeware">Freeware</a></td>
      <td>Freeware is software, most often proprietary, that is distributed at no monetary cost to the end user. There is no agreed-upon set of rights, license, or EULA that defines freeware unambiguously; every publisher defines its own rules for the freeware it offers.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Limited_liability">Limited liability</a></td>
      <td>Limited liability is a legal status where a person's financial liability is limited to a fixed sum, most commonly the value of a person's investment in a corporation, company or partnership. If a company that provides limited liability to its investors is sued, then the claimants are generally entitled to collect only against the assets of the company, not the assets of its shareholders or other investors.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/The_Liability">The Liability</a></td>
      <td>The Liability (also known as The Hitman's Apprentice) is a 2013 British black comedy crime-thriller film directed by Craig Viveiros and written by John Wrathall. The film stars Tim Roth, Talulah Riley, Jack O'Connell and Peter Mullan.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Vicarious_liability">Vicarious liability</a></td>
      <td>Vicarious liability is a form of a  strict, secondary liability that arises under the common law doctrine of agency, respondeat superior, the responsibility of the superior for the acts of their subordinate or, in a broader sense, the responsibility of any third party that had the "right, ability or duty to control" the activities of a violator. It can be distinguished from contributory liability, another form of secondary liability, which is rooted in the tort theory of enterprise liability because, unlike contributory infringement, knowledge is not an element of vicarious liability.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Legal_liability">Legal liability</a></td>
      <td>In law, liable means  "responsible or answerable in law; legally obligated". Legal liability concerns both civil law and criminal law and can arise from various areas of law, such as contracts, torts, taxes, or fines given by government agencies.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Trade_secret">Trade secret</a></td>
      <td>Trade secrets are a type of intellectual property that includes formulas, practices, processes, designs, instruments, patterns, or compilations of information that have inherent economic value because they are not generally known or readily ascertainable by others, and which the owner takes reasonable measures to keep secret. Intellectual property law gives the owner of a trade secret the right to restrict others from disclosing it.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>STRATEGIC DIAGNOSTICS INC/DE/      Item 1A Risk Factors       The following is a discussion of <font color="blue">certain <font color="blue">significant</font> risk factors</font> that could     have an <font color="blue">adverse impact</font> our financial condition, performance and prospects</td>
    </tr>
    <tr>
      <td>Our <font color="blue">products must gain market <font color="blue">acceptance</font></font> for us to <font color="blue">increase revenue</font></td>
    </tr>
    <tr>
      <td>Any product that we sell or develop <font color="blue">must compete</font> for market <font color="blue">acceptance</font> and     market share</td>
    </tr>
    <tr>
      <td>An important factor will be the timing of <font color="blue">market introduction</font>     of <font color="blue"><font color="blue">competitive</font> products</font></td>
    </tr>
    <tr>
      <td>Accordingly, the relative speed with which we and     competing companies can develop products, complete any required approval     processes, and supply <font color="blue">commercial quantities</font> of the products to the market     will be an important element of <font color="blue">market success</font></td>
    </tr>
    <tr>
      <td><font color="blue">Significant </font><font color="blue"><font color="blue">competitive</font> factors</font> include:                                          •       timing and scope of <font color="blue"><font color="blue">regulatory</font> approval</font>;                                            •       <font color="blue">product availability</font>;                                            •       awareness and <font color="blue">acceptance</font> of our products and their <font color="blue">application</font>;                                            •       channels to market;                                            •       marketing and <font color="blue">sales capabilities</font>;                                            •       <font color="blue">product <font color="blue">attributes</font> relative</font> to its cost;                                            •       price; and                                            •       exclusivity, through <font color="blue">patent protection</font> or otherwise</td>
    </tr>
    <tr>
      <td>Our research, <font color="blue">development</font> and <font color="blue"><font color="blue">commercialization</font> efforts may</font> not succeed or     our <font color="blue"><font color="blue">competitors</font> may</font> develop and <font color="blue">commercialize</font> more <font color="blue">effective</font> or successful     <font color="blue">diagnostic products</font></td>
    </tr>
    <tr>
      <td>In  order  to <font color="blue">remain <font color="blue">competitive</font></font>, we <font color="blue">must regularly commit</font> substantial     resources to research and <font color="blue">development</font> and the <font color="blue">commercialization</font> of new     products and/or antibody services</td>
    </tr>
    <tr>
      <td>16     ______________________________________________________________________       [107]Back to <font color="blue">Contents       </font>The research and <font color="blue">development</font> process generally takes a <font color="blue"><font color="blue">significant</font> amount</font> of     time <font color="blue">from inception</font> to <font color="blue">commercial product launch</font></td>
    </tr>
    <tr>
      <td>This process is conducted     in <font color="blue">various stages</font></td>
    </tr>
    <tr>
      <td>During <font color="blue">each stage there</font> is a substantial risk that we     will not achieve our goals on a <font color="blue">timely basis</font>, or at all, and we may have to     abandon  a  product  or  <font color="blue"><font color="blue">technology</font> platform</font> in which we have invested     substantial amounts</td>
    </tr>
    <tr>
      <td>Other companies have products that <font color="blue">compete with</font> our products, and also may     develop <font color="blue">effective</font> and <font color="blue"><font color="blue">commercially</font> successful products</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue"><font color="blue">competitors</font> may</font>     succeed in developing or <font color="blue">commercializing products</font> that are either more     <font color="blue">effective</font> than ours, or that they market before we <font color="blue">market <font color="blue">new products</font></font> that     we may develop</td>
    </tr>
    <tr>
      <td>There may be additional <font color="blue"><font color="blue">competitive</font> products</font> about which we are not aware</td>
    </tr>
    <tr>
      <td>If our <font color="blue">competitors</font> are able to reach the <font color="blue">commercial market</font> before we are,     this  could have a material adverse effect on our ability to reach the     <font color="blue">commercial market</font> and sell our products</td>
    </tr>
    <tr>
      <td>Many of the <font color="blue">organizations competing with us</font> have <font color="blue">substantially greater</font>     capital resources, larger research and <font color="blue">development</font> staffs and <font color="blue">facilities</font>,     greater  experience in product <font color="blue">development</font> and in obtaining <font color="blue">regulatory</font>     approvals, and <font color="blue">greater <font color="blue">manufacturing</font></font> and <font color="blue">marketing capabilities than</font> we do</td>
    </tr>
    <tr>
      <td>These organizations also <font color="blue">compete with</font> us to <font color="blue">license <font color="blue">proprietary</font> <font color="blue">technology</font></font></td>
    </tr>
    <tr>
      <td>If we fail to obtain or maintain the <font color="blue"><font color="blue">regulatory</font> approval</font>s necessary to sell     our products, sales could be <font color="blue"><font color="blue">negatively</font> impacted</font></td>
    </tr>
    <tr>
      <td>Generally, at this time, our test kits do not require pre-market approval by     the US Food and Drug Administration (the “FDA”) or any other <font color="blue">regulatory</font>     agency</td>
    </tr>
    <tr>
      <td>However, <font color="blue">agencies such as</font> the EPA, FDA and the Food Safety and     Inspection Service of the US Department of Agriculture are engaged in     testing environmental samples and, <font color="blue">together with</font> the Association of Official     Analytical  Chemists  International (“AOAC”), maintain <font color="blue">compilations</font> of     official  methods for use in testing for <font color="blue">environmental contaminants</font> in     certain market segments, along with procedures and <font color="blue">guidelines</font> for validating     new methods</td>
    </tr>
    <tr>
      <td>The failure of these programs to accept the Company’s products     could have an <font color="blue">adverse impact</font> on our business</td>
    </tr>
    <tr>
      <td>The <font color="blue">environmental legislation</font>     and <font color="blue">regulations</font> that the Company believes are <font color="blue">most applicable</font> to its current     business are RCRA, CERCLA, TSCA, FIFRA and the Pure Food and Drug Act</td>
    </tr>
    <tr>
      <td>For     analysis of water and wastewater, the Safe Drinking Water Act, the Clean     Water Act and the NPDES <font color="blue">permitting program under</font> the <font color="blue">Clean Water Act </font>also     will  be  <font color="blue">significant</font> to the Company’s business</td>
    </tr>
    <tr>
      <td>As the utility of the     Company’s Microtox^® <font color="blue">products continues</font> to be widely recognized in drinking     water  security <font color="blue">application</font>s, <font color="blue">regulations</font> and <font color="blue">mandates associated with</font>     Homeland  Security  programs  may also have an <font color="blue">impact on</font> the Company’s     business</td>
    </tr>
    <tr>
      <td>Although the Company’s <font color="blue">products may</font> not be regulated, the <font color="blue">industry segments</font>     into  which its products are sold may be regulated, and demand for the     Company’s <font color="blue">products may</font> be <font color="blue">driven by</font> these <font color="blue">regulations</font> or the <font color="blue">lack thereof</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">regulations</font> vary from country to country</td>
    </tr>
    <tr>
      <td>The <font color="blue">regulatory</font> environments     in which we <font color="blue">compete could</font> change dramatically, which may require us to incur     <font color="blue">significant</font> costs in obtaining or maintaining <font color="blue"><font color="blue">regulatory</font> approval</font>s</td>
    </tr>
    <tr>
      <td>If we do     not obtain or maintain <font color="blue"><font color="blue">regulatory</font> approval</font>s to <font color="blue">enable us</font> to market our     products in the <font color="blue">United States </font>or elsewhere, or if the approvals are subject     to <font color="blue">significant</font> <font color="blue">restrictions</font>, the demand for our <font color="blue">products may</font>be <font color="blue">negatively</font>     impacted</td>
    </tr>
    <tr>
      <td>If we do not match our <font color="blue">product <font color="blue">manufacturing</font> capability</font> to <font color="blue">customer demand</font>     in a cost-<font color="blue">effective</font> manner, our <font color="blue">product sales may suffer</font></td>
    </tr>
    <tr>
      <td>Our  product  sales  depend  upon,  among other things, our ability to     <font color="blue">manufacture</font> our products in <font color="blue">commercial quantities</font> and in a cost-<font color="blue">effective</font>     manner</td>
    </tr>
    <tr>
      <td>To  the extent there is a dramatic increase in demand for our     products, we may not be able to <font color="blue">manufacture</font> the products in a quick and cost     <font color="blue">effective</font> manner</td>
    </tr>
    <tr>
      <td>Our <font color="blue">manufacturing</font> success also depends, in part, on our     ability to <font color="blue">transition products from research</font> and <font color="blue">development</font> into commercial     scale  <font color="blue">manufacturing</font></td>
    </tr>
    <tr>
      <td>If we are not successful in this transition, our     ability to produce <font color="blue">products may</font> suffer</td>
    </tr>
    <tr>
      <td>Our business <font color="blue">could suffer</font> if we <font color="blue">cannot attract</font>, retain and <font color="blue">motivate skilled</font>     personnel</td>
    </tr>
    <tr>
      <td>Our <font color="blue">success depends on</font> our <font color="blue">continued ability</font> to attract, retain and motivate     <font color="blue">highly qualified personnel</font>, including our <font color="blue">current executive officers</font> and     other <font color="blue">key employees</font></td>
    </tr>
    <tr>
      <td>If <font color="blue">such executive officers</font> or other <font color="blue">key employees</font> were     to leave and the Company were unable to obtain <font color="blue">adequate replacements</font>, the     Company’s operating results could be <font color="blue">adversely affected</font></td>
    </tr>
    <tr>
      <td>In addition, the     Company’s <font color="blue">growth depends on</font> its ability to attract,                                         17     ______________________________________________________________________       [108]Back to <font color="blue">Contents       </font>retain and <font color="blue">motivate skilled</font> employees, and on the ability of its officers     and <font color="blue">key employees</font> to <font color="blue">manage growth successfully</font></td>
    </tr>
    <tr>
      <td>It is <font color="blue">difficult</font> and costly to protect our <font color="blue"><font color="blue">intellectual property</font> rights</font>, and     we <font color="blue">cannot ensure</font> the protection of these rights; we may be <font color="blue">sued by others</font>     for infringing their <font color="blue"><font color="blue">intellectual property</font> rights</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">commercial success will depend</font> in part on obtaining <font color="blue"><font color="blue">patent protection</font> on</font>     our products and <font color="blue">successfully defending</font> these <font color="blue">patents against third party</font>     <font color="blue">challenges</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">patent positions</font> of <font color="blue"><font color="blue">technology</font> driven companies</font> can be     highly  uncertain  and  involve  complex  legal and factual questions</td>
    </tr>
    <tr>
      <td>Accordingly, we <font color="blue">cannot predict</font> the breadth of claims allowed in our patents</td>
    </tr>
    <tr>
      <td>Others have filed, and in the future are likely to file, patent <font color="blue">application</font>s     covering  products  and  <font color="blue">technologies</font>  that  are similar, identical or     <font color="blue">competitive</font> to ours, or important to our business</td>
    </tr>
    <tr>
      <td>We cannot be certain that     any patent <font color="blue">application</font> owned by a <font color="blue">third party will</font> not have <font color="blue">priority over</font>     patent <font color="blue">application</font>s filed or <font color="blue">licensed by us</font>, or that we or our <font color="blue">licensors</font>     will not be involved in <font color="blue">interference proceedings</font> before the <font color="blue">United States </font>    Patent and Trademark Office</td>
    </tr>
    <tr>
      <td>Although no third party claims of <font color="blue">infringement</font> are outstanding against the     Company, <font color="blue">others may</font> hold <font color="blue">proprietary</font> rights that <font color="blue">will prevent</font> our product     candidates from being <font color="blue">marketed unless</font> we can obtain a license to those     <font color="blue">proprietary</font>  rights</td>
    </tr>
    <tr>
      <td>Any  patent  related  legal  action  against our     <font color="blue">collaborators</font>  or us claiming damages and seeking to <font color="blue">enjoin commercial</font>     <font color="blue">activities</font>  relating to our products and processes could subject us to     potential  <font color="blue">liability</font> for damages and require us to obtain a license to     continue to <font color="blue">manufacture</font> or market the <font color="blue">affected products</font> and processes</td>
    </tr>
    <tr>
      <td>We     <font color="blue">cannot predict</font> whether we <font color="blue">would prevail</font> in any of these actions or that any     license required under any of these <font color="blue">patents would</font> be made <font color="blue">available on</font>     <font color="blue">commercially</font>  acceptable  terms,  if  at all</td>
    </tr>
    <tr>
      <td>If we <font color="blue">become involved</font> in     <font color="blue">litigation</font>, it <font color="blue">could consume</font> substantial managerial and <font color="blue">financial resources</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">rely on <font color="blue">trade secrets</font></font> to <font color="blue">protect <font color="blue">technology</font></font> in cases where we believe     <font color="blue">patent protection</font> is not <font color="blue">appropriate</font> or obtainable</td>
    </tr>
    <tr>
      <td>However, <font color="blue">trade secrets</font>     are <font color="blue">difficult</font> to protect</td>
    </tr>
    <tr>
      <td>While we require <font color="blue">certain employees</font> and suppliers     to <font color="blue">enter into <font color="blue">confidentiality</font> agreements</font>, we may not be able to protect     <font color="blue">adequately</font> our <font color="blue">trade secrets</font> or other <font color="blue">proprietary</font> information</td>
    </tr>
    <tr>
      <td>If we cannot     maintain the <font color="blue">confidentiality</font> of our <font color="blue">technology</font>, our ability to receive     <font color="blue">patent protection</font> or protect our <font color="blue">proprietary</font> information may be imperiled</td>
    </tr>
    <tr>
      <td>If product <font color="blue">liability</font> lawsuits are <font color="blue">successfully brought against us</font>, we may     incur   substantial  <font color="blue">liabilities</font>  and  may  have  to  limit  or  cease     <font color="blue">commercialization</font> of our products</td>
    </tr>
    <tr>
      <td>The testing and marketing of our products gives rise to an <font color="blue">inherent risk</font> of     product  <font color="blue">liability</font></td>
    </tr>
    <tr>
      <td>If we <font color="blue">cannot successfully defend ourselves against</font>     product  <font color="blue">liability</font>  claims, we may incur substantial <font color="blue">liabilities</font> or be     required to limit or cease <font color="blue">commercialization</font> of our products</td>
    </tr>
    <tr>
      <td>We currently     carry product <font color="blue">liability</font> insurance at a level we believe is <font color="blue">commercially</font>     reasonable, although there is no assurance that it will be adequate to cover     claims that may arise</td>
    </tr>
    <tr>
      <td>In <font color="blue">certain customer contracts</font> we <font color="blue">indemnify third</font>     parties for certain product <font color="blue">liability</font> claims related to our products</td>
    </tr>
    <tr>
      <td><font color="blue">These     </font><font color="blue">indemnification obligations may</font> cause us to pay <font color="blue">significant</font> sums of money     for claims that are <font color="blue">covered by</font> these <font color="blue">indemnifications</font></td>
    </tr>
    <tr>
      <td>18     ______________________________________________________________________       [109]Back to <font color="blue">Contents       </font>If  our Company does not produce <font color="blue">future taxable income</font>, our ability to     realize the benefits of <font color="blue">deferred tax assets could</font> be impaired</td>
    </tr>
    <tr>
      <td>As  of  <font color="blue">December  </font>31, 2005, the Company had <font color="blue">federal net</font> operating loss     <font color="blue">carryforwards</font>, including those acquired in the Company’s <font color="blue">past acquisitions</font>,     of  <font color="blue">approximately</font>  dlra18cmam873, which, if not utilized, begin to expire as     follows:         Year                                      Amount of                                    NOL (in                                   thousands)         _________________________________________________________________           _________________________________________________________________       _________________________________________________________________           2007                                        $ 946       2008                                         2cmam565       2009                                         3cmam297       2010                                         5cmam109       2017                                          760       2018                                         1cmam327       2019                                          550       2020                                           66       2021                                           51       2022                                         2cmam253       2024                                         1cmam824       2025                                          125         _________________________________________________________________       _________________________________________________________________           Total                                       $ 18cmam873         _________________________________________________________________       _________________________________________________________________         Based on the best information available to the Company today, the <font color="blue">Company     </font>expects to have sufficient <font color="blue">future taxable income</font> to <font color="blue">utilize such</font> NOLs prior     to the expiration of the net operating loss carry forwards</td>
    </tr>
    <tr>
      <td><font color="blue">The Tax Reform Act </font>of 1986 (the Act) limits the <font color="blue">annual use</font> of net operating     loss and research and <font color="blue">development</font> tax credit <font color="blue">carryforwards</font> (after certain     ownership changes, <font color="blue">as defined by</font> the Act)</td>
    </tr>
    <tr>
      <td>The <font color="blue">application</font> of these limits     could <font color="blue">significant</font>ly restrict our ability to utilize <font color="blue">carryforwards</font></td>
    </tr>
    <tr>
      <td>Of our     total net operating loss <font color="blue">carryforwards</font>, dlra14cmam794 is subject to <font color="blue">limitations</font>,     since a cumulative change in ownership of more than 50prca has occurred within     a <font color="blue">three year period with respect</font> to those net operating loss <font color="blue">carryforwards</font></td>
    </tr>
    <tr>
      <td>Because <font color="blue">United States </font><font color="blue">tax laws limit</font> the time <font color="blue">period during which</font> these     <font color="blue">carryforwards</font> may be <font color="blue">applied against future taxes</font>, we may not be able to     take full advantage of these <font color="blue">attributes</font> for Federal <font color="blue">income tax purposes</font> if     we do not have <font color="blue">future taxable income</font> against which to use the <font color="blue">carryforwards</font>     before they expire</td>
    </tr>
    <tr>
      <td>Our results of <font color="blue">operations</font> may fluctuate, which could cause <font color="blue">volatility</font> in our     stock price</td>
    </tr>
    <tr>
      <td>Our results of <font color="blue">operations</font> may fluctuate <font color="blue">significant</font>ly in the future as a     result of a number of factors, many of which are outside of our control</td>
    </tr>
    <tr>
      <td>These factors include, but are not limited to:                                          •       unanticipated events associated with <font color="blue">regulatory</font> changes;                                            •       <font color="blue">general economic conditions</font>;                                            •       <font color="blue">seasonality</font>;                                            •       <font color="blue">acceptance</font> of our products;                                            •       the success of products <font color="blue">competitive</font> with ours;                                            •       expenses associated with <font color="blue">development</font> and protection of <font color="blue">intellectual property</font>     matters;                                            •       <font color="blue">establishing</font> or maintaining commercial scale <font color="blue">manufacturing</font> capabilities;                                            •       the timing of expenses related to <font color="blue">commercialization</font> of <font color="blue">new products</font>;                                            •       the timing and success in building our <font color="blue">distribution channels</font>;       The results of our <font color="blue">operations</font> may fluctuate <font color="blue">significant</font>ly from quarter to     quarter and may not <font color="blue">meet expectations</font> of <font color="blue">securities analysts</font> and investors</td>
    </tr>
    <tr>
      <td>19     ______________________________________________________________________       [110]Back to <font color="blue">Contents       </font>If we <font color="blue">use hazardous materials</font> in a manner that causes injury or violates     laws, we may be liable for damages</td>
    </tr>
    <tr>
      <td>Our  research and <font color="blue">development</font> <font color="blue">activities</font> involve the <font color="blue">controlled use</font> of     potentially harmful biological materials as well as hazardous materials,     <font color="blue">chemicals</font>  and  <font color="blue">various radioactive compounds</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">use radioactivity</font> in     conducting biological assays and we <font color="blue">use solvents</font> that could be flammable in     conducting our research and <font color="blue">development</font> <font color="blue">activities</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot completely</font>     eliminate the risk of <font color="blue">accidental <font color="blue">contamination</font></font> or <font color="blue">injury from</font> the use,     storage, handling or disposal of these materials</td>
    </tr>
    <tr>
      <td>In the event of     <font color="blue">contamination</font> or injury, we could be held liable for damages that result,     and any <font color="blue">liability</font> could exceed our resources</td>
    </tr>
    <tr>
      <td>We are subject to federal,     state and <font color="blue">local laws</font> and <font color="blue">regulations</font> governing the use, storage, handling     and disposal of these materials and <font color="blue">specified waste products</font></td>
    </tr>
    <tr>
      <td>The cost of     <font color="blue">compliance with</font> these laws and <font color="blue">regulations</font> could be <font color="blue">significant</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">antibody production process utilizes various</font> species of animals that     <font color="blue">could contract disease</font> or die, <font color="blue">interrupting</font> business <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">antibody production process utilizes animals</font> to produce <font color="blue">antibodies</font></td>
    </tr>
    <tr>
      <td>We     <font color="blue">cannot completely</font> eliminate the risks of <font color="blue">animals contracting disease</font> or a     disaster that could cause death to valuable <font color="blue">production animals</font></td>
    </tr>
    <tr>
      <td>Disease or     death on a broad scale could interrupt business <font color="blue">operations</font> as animals are a     key part of the <font color="blue">antibody production operation</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">difficult</font>ies of operating in <font color="blue">international markets may harm sales</font> of our     products</td>
    </tr>
    <tr>
      <td>The   international  nature  of  our  business  subjects  us  and  our     representatives, agents and <font color="blue">distributors</font> to the laws and <font color="blue">regulations</font> of the     <font color="blue">jurisdictions</font> in which they operate, and in which our products are sold</td>
    </tr>
    <tr>
      <td>The     types of risks that we face in international <font color="blue">operations</font> include, but are not     limited to:                                          •       the imposition of <font color="blue">governmental controls</font>;                                            •       logistical <font color="blue">difficult</font>ies in managing international <font color="blue">operations</font>; and                                            •       <font color="blue">fluctuations</font> in <font color="blue">foreign currency exchange rates</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">international sales</font> and <font color="blue">operations</font> may be limited or disrupted if we     <font color="blue">cannot successfully meet</font> the <font color="blue">challenges</font> of operating <font color="blue">internationally</font></td>
    </tr>
  </tbody>
</table>